[Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data]. / Metastasiertes kastrationsresistentes Prostatakarzinom : Neues zu Cabazitaxel unter Berücksichtigung der aktuellen Datenlage.
Urologe A
; 57(1): 34-39, 2018 Jan.
Article
in De
| MEDLINE
| ID: mdl-29071398
ABSTRACT
BACKGROUND:
At the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented.OBJECTIVES:
The focus is on the clinical impact of these data. MATERIALS ANDMETHODS:
A group of German experts in the field of urogenital-oncologic expertise discussed the clinical impact with respect to the current data.RESULTS:
The study results support the current clinical data. They confirm the efficacy and safety of cabazitaxel beyond first-line therapy with docetaxel for patients with mCRPC.CONCLUSIONS:
Cabazitaxel is an important treatment option after docetaxel progression. With respect to the performance status of a patient, it is adequate to reduce the dosage to 20 mg/m2 cabazitaxel.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neoplasms, Second Primary
/
Taxoids
/
Prostatic Neoplasms, Castration-Resistant
Type of study:
Clinical_trials
Limits:
Humans
/
Male
Language:
De
Journal:
Urologe A
Year:
2018
Document type:
Article